Please login to the form below

Not currently logged in
Email:
Password:

Deal Watch

This page shows the latest Deal Watch news and features for those working in and with pharma, biotech and healthcare.

The M&A trend in pharma

The M&A trend in pharma

The lion's share of deal-making in 2014 continued to revolve around Western markets. ... Read more about pharma's M&A activity in the latest Deal Watch article.

Latest news

  • The hunted now hunt: biotechs become buyers The hunted now hunt: biotechs become buyers

    Biotech deals feature in our latest Deal Watch article.

  • Pharma deals during August 2012 Pharma deals during August 2012

    Fitting well into Chiesi's respiratory franchise, the deal includes milestones payments of $60m. ... This deal allows for collaboration on three microRNA targets including the lead microRNA-33 for atherosclerosis.

  • Pharma deals for June 2012 Pharma deals for June 2012

    This was another example of biotech muscle flexing with Amylin previously rejecting BMS's earlier takeover offer, reported to have been $3.5bn (highlighted in last month's Deal Watch). ... Overall, as noted in previous Deal Watch articles, platform deals

  • Pharma deals for May 2012 Pharma deals for May 2012

    Acquire or license? On the theme of product acquisitions noted above, there are two further examples in this month's deal summary table. ... Emerging markets. Following the theme of previous Deal Watches in the emerging markets space, both Takeda and UCB

  • Pharma deals for March 2012 Pharma deals for March 2012

    Another company which features regularly in Deal Watch headlines is Valeant, this time making a significant move to consolidate its operations in Russia and the CIS. ... Originally reported in Deal Watch in October 2010, this month Pfizer announced the

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Deal Watch January 2018. One key question for 2018 is whether the recent US tax changes will have an effect on M&A in our industry - time will tell. ... Teva/Alder Biopharmaceuticals patent settlement. We have featured Teva in Deal Watch over the last

  • Pharma deals continue to slide Pharma deals continue to slide

    Deal Watch investigates. There is plenty of evidence that the number and value of biopharma M&A and licensing deals in 2016 and 2017 is declining. ... This month Deal Watch reviews the potential impact of some of the macroeconomic factors and the impact

  • Deal Watch - May 2017 Deal Watch - May 2017

    Deal Watch - May 2017. An interesting month but expect big-ticket licensing deals to be few and far between from now on. ... In both cases the upfront is around 44% of the total deal value.

  • Deal Watch March 2017 Deal Watch March 2017

    Deal Watch March 2017. Sanofi, MedImmune, AstraZeneca, Astellas, Novartis and more feature in this month's pharma deals round-up. ... Each month the Deal Watch team ploughs our merry way through the details of 600 plus deals to bring you the edited

  • Deal Watch February 2017 Deal Watch February 2017

    Deal Watch February 2017. Actelion, Johnson &Johnson, Sanofi, Takeda and more feature in this month's pharma deals round-up. ... The deal also includes a licence to AKB-5169 (formerly JNJ5169), an oral, preclinical stage compound for inflammatory bowel

More from intelligence
Approximately 78 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics